Last reviewed · How we verify

Padcev Ejfv — Competitive Intelligence Brief

Padcev Ejfv (enfortumab-vedotin) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Nectin-4 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Padcev Ejfv (enfortumab-vedotin) — Astellas Pharma. Enfortumab vedotin-ejfv binds to Nectin-4, internalizes, releases MMAE, disrupting microtubules and causing cell death.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Padcev Ejfv TARGET enfortumab-vedotin Astellas Pharma marketed Nectin-4 2019-01-01
Padcev AGS-22M6E Astellas Pharma marketed Nectin-4 2019-01-01
Enfortumab padcev Astellas Pharma marketed Nectin-4 2019-01-01
ENFORTUMAB VEDOTIN ENFORTUMAB VEDOTIN marketed Nectin-4 2019-01-01
enfortumab vedotin (EV) enfortumab vedotin (EV) Astellas Pharma Global Development, Inc. phase 3 Monoclonal antibody-drug conjugate Nectin-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Padcev Ejfv — Competitive Intelligence Brief. https://druglandscape.com/ci/enfortumab-vedotin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: